Immunoblotting and staining verified that overexpression of HuR was followed by the upregulation of BCAT1 expression in CRPC cell lines and clinical CRPC tissues, and genetic modification further confirmed that HuR knockout decreased BCAT1 expression in CRPC cells and tumour xenografts. This evidence concerns the gene ELAVL1 and neoplasm.